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for more robust detections of small relative differences in susceptibility (32, 33) . Overall, 114 collateral responses were observed in 40.5% (243/600) of possible instances (Table S2) ; 115 of these, roughly half, 47% (115/243), were associated with only a 1.5 and 2-fold change 116 in IC 90 . Such small changes would not be observed by typical 2-fold antimicrobial 117 susceptibility testing methods frequently used in clinical laboratories. 118
119
Overall CR was more frequent than CS, 151 versus 92 instances (Table S2) , and 120 collateral networks varied considerably between AMR groups. We observed 20 cases of 121 conserved collateral responses ( Fig. 1) , where CR or CS to a specific antimicrobial was 122 found in ≥ 50% of the mutants within an AMR group, defined as CR 50 During the selection of AMR mutants, we often observed conspicuous changes to colony 132 size for all AMR groups, suggesting that resistant mutants had reduced bacterial fitness. 133
To test this, we measured the growth rates of AMR mutants and compared these to the 134 respective WT strains (Fig. S4) 
8%). 149
Additionally, CS responses found for the CIP R mutants were the most conserved in our 150 dataset, with CS to GEN occurring in 8 of 10 strains and CS to FOS in 7 of 10 strains. 151 GEN and other aminoglycosides are important for the treatment of a wide range of 152 hospital infections (34), while FOS is primarily used for treatment of uncomplicated 153 urinary tract infections (35, 36). The CIP R mutants were also unique in the magnitude of 154 observed changes, with cases of CR close to 30-fold and CS as high as 6-fold changes in 155 IC 90 (Fig. S2) . Only CIP R isolates displayed potential clinically relevant CR, where six 156 strains had IC 90 values above the clinical breakpoint for resistance to CHL and a single 157 strain (K56-68 CIP R ) was above the AMX breakpoint. 158 between the AMR groups could be attributed to mutations causing resistance in each 161 strain. Using whole genome sequencing we identified a total of 150 mutations in the 162 AMR mutants (Table S3) . Of these, 88 mutations affect previously described or putative 163 AMR associated genes, gene regions, or pathways ( Table S3) . The remaining mutations 164 were found in other cellular processes with no known association to antimicrobial 165 resistance (e.g. metabolic pathways and virulence factors), such as mutation to the FimE 166 regulator of FimA that was frequently observed in MEC R mutants (Table S3) . Aside 167 from FimE, we did not observe similar mutations in non-AMR associated regions across 168 strains of the same AMR group (parallel evolution), suggesting that such mutations had 169 limited, if any effect on collateral responses in this study. For each of the 40 AMR 170 mutants at least one putative resistance mechanism was identified, including mutations to 171 previously described antimicrobial drug targets and promoters of drug targets, drug 172 modifying (activating) enzymes, regulators of efflux pumps, RNA polymerases and 173 mutations to other metabolic and biochemical processes that may contribute to resistance 174 (Table 3) . Briefly, all but one CIP R mutant contained mutations in gyrA and efflux 175 regulatory genes and gene-regions likely affecting efflux expression (acrAB and/or 176 mdtK), while one strain had only drug target mutations and displayed the well-describedmutations are frequently found in surveys of clinical isolates (37-40). NIT R mutants had 179 mutations in one or both nitro-reductases (nfsA, nfsB) and the majority of strains had 180 additional mutations in mprA that encodes an efflux regulator of EmrAB-TolC pump 181 have in these WT strains since all were phenotypically pan-susceptible (Fig. S1) . 201
However, the ParE mutation could contribute to CIP R levels in K56-78, as the K56-78 202 WT was among the higher WT values for CIP (0.015 µg/mL) (Fig. S1) approaches were used to investigate the extent to which genetic (strain) background, 208 AMR group, the putative mechanism of resistance in particular efflux-related mutations 209 (Table S3) , growth rate and the fitness cost of resistance explain the total variation in 210 collateral responses. All the above factors were investigated individually and the related 211 models are found in the supplementary material (Fig. S5A) . Throughout the remaining 212 analyses we focus mainly on efflux-related mutations rather than AMR group to 213 explicitly address putative mechanisms of resistance and on relative fitness rather than 214 the growth rate. We estimated several models with individual, or a combination of, 215 factors to assess their effect size and significance given some level of co-linearity 216 between fitness and efflux type (Fig 2, Fig. S5C-F) . A model including strain 217 background, relative fitness and efflux-related mutations as factors explained 62.53% of 218 the total variation in IC 90 values ( Fig. 2A, Table S4 ). In this three-factor model there 219 was clear separation of the mutants by AMR group. The CIP R mutants showed strong 220 CR towards TEM, CHL, CAZ and AMX separating this AMR group from the others 221 along the first ordination axis. Along the second ordination axis, MEC R isolates were 222 distinct, had CR to TEM, and were more likely to have CS towards drugs such as AZT 223 and CHL ( Fig. 2A) . Both efflux type and relative fitness were significant predictors 224 when tested alone and in combination ( Table S4) . The model ( Fig. 2A) also revealed that 225 strain background had a limited, non-significant contribution. Even when modeled alone 226 (Fig. S5A) , strain background only accounted for 6.53% of the variation and was nonWe initially hypothesized that genetic background would significantly affect collateral 230 responses. Our data suggest that it does not. Arguably, the inclusion of IC 90 data from the 231 drugs to which primary resistance was selected for could confound the analysis, despite 232 our efforts to minimize these effects using log transformed data. We used the same 233 approaches to assess a subset of collateral responses, excluding data for all of the 40 234 AMR mutants to five antimicrobials containing the drugs used for selection (CIP, MEC, 235 NIT, TMP) and SXT. Within the subset model, patterns consistent with the full model 236
were observed, but with a lower degree of clustering by AMR group (Fig. 2B) . For 237 example, the K56-2 CIP R mutant is now co-localized with the MEC R isolates, indicating 238 that this isolate is distinct from other CIP R mutants, which still showed strong tendencies 239 of CR to TEM, CHL, CAZ and AMX. Despite these changes, efflux type and fitness 240 were still significant predictors of collateral networks, whereas strain background 241 remained non-significant in models, both in combination and alone (Fig. S5B, Table S4 ). 242
Mutations in efflux-related genes and gene regulators were the strongest predictor of 243 collateral responses tested, explaining over 33% of the variation in the subset. Fitness 244 alone also had significant predictive value, but to a lesser extent (17% variation 245 explained). It is important to note that we observed correlation between efflux mutations 246 and relative fitness that is likely explained by reduced fitness resulting from the cost of 247 overexpression of efflux pump(s) (38) . 248
249
To investigate the influence of resistance mechanism on IC 90 variation at a higher 250 resolution, we modeled each AMR group separately relating the putative resistance 251 mechanism and fitness separately and in combination (Fig. S5) . However potentially due 252 to a lower number of samples within AMR groups and more detailed classification of the 253 resistance mechanism, these factors had varying degrees of contribution. For TMP R and 254
CIP
R AMR groups, resistance mechanism was non-significant, but it was a significant 255 factor for NIT R and MEC R mutants. Fitness was a significant factor of variation only for 256 the MEC R group and similarly, combination models using both resistance mechanism and 257 fitness were non-significant for all AMR groups, with the exception of the MEC R group. clinically relevant examples of CS phenotypes that appeared independent of putative 306 mechanism of resistance. We show that CIP R E. coli strains displayed CS towards GEN, 307 FOS, ETP and COL, and these phenotypes were conserved across multiple mechanisms 308 of resistance. These results parallel those of a recent study on P. aeruginosa clinical 309
isolates from cystic fibrosis patients, where CIP R was associated with CS to GEN, FOS 310 and COL. Taken together these data support the presence of general conserved collateral 311 networks that may both affect the population dynamics of AMR during treatment and 312
counter-select for resistance as recently indicated (30). 313 314
We assumed a priori that genetic background, AMR group, resistance mechanism, and 315 the fitness cost of resistance could potentially affect the generality, sign and magnitude of 316 collateral networks in clinical E. coli strains. Despite the fact that some collateral 317 responses are conserved across different strains and mechanisms of resistance, our 318 multivariate statistical approaches show overall that mechanism of resistance is the key 319 predictor of CS and CR variability. This is primarily the case for efflux related mutations.
However, mechanism of resistance also significantly contributed to the observed CS and 321 CR variation in the MEC mutants where no efflux mutations were found. The presented 322 data are consistent with earlier reports based on multiple AMR mutants derived from 323 single strains with different resistance mechanisms towards specific antimicrobials (21, 324 22, 48). Our finding that genetic background did not significantly contribute to collateral 325 responses is an important addition to these earlier studies. Finally, we found that the 326 fitness cost of resistance also contributed significantly to the observed variation in CS 327 and CR, despite some overlap in explanatory power due to the observed correlation 328 between efflux-related mutations and reduced fitness. Taken together, our data and 329 previous reports indicate that applied use of collateral networks in future treatment 330 strategies may be dependent on rapid identification of specific resistance mechanisms. 331
Moreover, clinical application of CS as a selection inversion strategy warrants further 332 investigations to ideally explore CS in isogenic backgrounds, representing several diverse 333 strains, with permutations of all known AMR-associated resistance traits. Such extensive 334 studies would likely provide valuable information on the mechanisms of CS. Other 335 confounding factors such as mobile genetic elements with heterogeneous resistance 336 determinants should also be investigated as they would likely influence and reduce the 337 predictability of collateral networks. 338 339 Selection inversion, as described by (20), depends on the cycling of drug pairs that 340 display reciprocal CS. We did not observe reciprocal CS between any of the four drugs 341 studied here that are widely used for treatment of urinary tract infections. However, we 342 asked if modest reductions and increases in antimicrobial susceptibilities would affect theand CR phenotypes to MPC assays and revealed that even a small 1.5-fold change in IC 90 345 could equally alter the MPC, resulting in a shift of the MSW. These results suggest that 346 antimicrobial treatment strategies informed by collateral networks could affect AMR 347 evolutionary trajectories. Sequential treatment using drug pairs that display CR would, 348 following resistance development, shift the MSW towards higher antimicrobial 349 field. Our analyses suggest that the fitness cost of resistance explains some variability in 374 the collateral networks reported here. While it is known that growth rates affect antibiotic 375 action (51), the underlying mechanism is currently unknown. It is also unclear if 376 collateral networks will be perturbed by compensatory evolution, which eliminates the 377 fitness costs of primary resistance (52-54). Finally, this and previous studies focus on 378 AMR development to a single drug and there is a complete lack of data on how multidrug 379 resistance, including resistance genes on mobile genetic elements, will affect collateral 380 networks. We are currently investigating these and other questions that will aid in our 381 understanding of collateral networks and their potential therapeutic application. in ≥ 50% of the isolates (CS 50 or CR 50 ), were confirmed by determining the mutation 428 prevention concentrations (MPCs), essentially as described previously (58). Briefly, 10 429 mL aliquots of an overnight culture were pelleted and re-suspended in 1 mL MHB, 430 estimated to contain ≥ 10 10 CFU (actual values were 1.4 x 10 10 -7 x 10 10 CFU). The 431 inoculum was split and spread onto four large (14 cm diameter) MHA-SA agar plates for 432 each antimicrobial concentration tested (4 -6 concentrations of a 2-fold dilution series). 433
The MPC was the lowest concentration with no visible growth after 48 h (Text S1).
minimum of two biological replicates. 436 437
Growth rate measurements. Growth curves of WT and AMR mutants were generated 438 in a Versamax plate reader (Molecular Devices Corporation, California, USA) with 439 constant shaking overnight. The OD 600 was measured every 10 minutes and growth rates 440 were estimated using GrowthRates v.2.1 software (59) (Text S1). 
453
WT genomes were assembled as described in Text S1. WT genomes were annotated 454 aligned to the corresponding annotated WT genome assembly. Reported SNPs had ≥ 10x 458 coverage depth and ≥ 90% variant base calls. SNPs present in the WT assembly or in at 459 least two AMR mutants of the same strain background were excluded. Genetic deletions 460 and rearrangements were identified in the structural variation report generated in SeqMan 461
Pro (DNASTAR) and were manually inspected and annotated using Gene Construction 462 Kit (Textco Biosoftware Inc., Raleigh, NC) and NCBI BLAST searches, respectively. Table S4 : Summary of the output from multivariate models. green, NIT R -gold, TMP R -purple), shape the assigned efflux type (circle -AcrAB-TolC + MdtK, square -EmrAB-TolC, diamondMdtK, triangle -no efflux-related mutations), and symbol size is proportional to relative fitness, where smaller size indicates a greater reduction in growth rate compared to the WT. Antimicrobial drug names indicate the tip of vectors that pass through the origin in the direction of increasing IC 90 fold change or CR (direction of steepest ascent). These vectors can be used to interpret the change in IC 90 for the antimicrobials shown, e.g. there was little change in the IC 90 of drugs centered near the origin, such as COL in B. The vector tip of relative fitness (brown) is also shown. Large grey symbols show the centroids (average effect) for all AMR mutants within a given efflux group (shape). The majority of explained variation is driven by primary resistances (A), where CIP R mutants (pink) cluster away from the other three AMR groups along the CIP vector, indicating higher resistance to CIP. CIP R mutants are likely to show CR to CHL, CAZ, TEM and AZT, but sensitivity to GEN, FOS and TMP. MEC R isolates primarily display low-level CS to most antimicrobials tested. TMP R and NIT R groups cluster together with relatively few collateral effects. The analysis of the subset (B) shows patterns consistent with the full model, but with less clustering by AMR group. However, in the redundancy analysis on a subset of the IC 90 fold changes (B) there is far less clustering of the AMR mutants by AMR group (color). . This would affect the probability of acquiring second step mutations leading to high-level resistance. Consequently, CS informed secondary therapies could reduce selection and thus propagation of first step mutants resulting in a reduced window of opportunity for second step mutations to occur. Dots represent bacteria resistant to a primary antibiotic (grey), spontaneous mutants with reduced susceptibility to a secondary drug (pink), or those with high-level resistance to the secondary drug (dark red). 
